Association of Renal Stress/Damage and Filtration Biomarkers with Subsequent AKI during Hospitalization among Patients Presenting to the Emergency Department
| Autor: | Mark Dominik Alscher, Niko Braun, Jing Shi, Martin Kimmel, Joerg Latus, Christoph Wasser, Daniel Kitterer |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
Epidemiology 030232 urology & nephrology Urine 030204 cardiovascular system & hematology Critical Care and Intensive Care Medicine chemistry.chemical_compound 0302 clinical medicine Hepatitis A Virus Cellular Receptor 1 Aged 80 and over biology Interleukin-18 Acute kidney injury Acute Kidney Injury Middle Aged Hospitalization Insulin-Like Growth Factor Binding Proteins Nephrology Area Under Curve Creatinine Predictive value of tests Female Sample collection Emergency Service Hospital medicine.medical_specialty Urinary system Fatty Acid-Binding Proteins 03 medical and health sciences Lipocalin-2 Predictive Value of Tests Internal medicine medicine Humans Cystatin C Aged Tissue Inhibitor of Metalloproteinase-2 Transplantation business.industry Original Articles medicine.disease Confidence interval Surgery ROC Curve chemistry biology.protein business Biomarkers Kidney disease |
| Zdroj: | Clinical Journal of the American Society of Nephrology. 11:938-946 |
| ISSN: | 1555-905X 1555-9041 |
| Popis: | Emergency departments (EDs) have a growing role in hospital admissions, but few studies address AKI biomarkers in the ED.Patients admitted to the internal medicine service were enrolled during initial workup in the ED at Robert-Bosch-Hospital, Stuttgart, Germany. Daily serum creatinine (sCr) and urine output (UO) were recorded for AKI classification by Kidney Disease Improving Global Outcomes (KDIGO) criteria. Cystatin C, kidney injury molecule-1, liver-type fatty acid-binding protein, and neutrophil gelatinase-associated lipocalin were measured in blood and urine, and IL-18, insulin-like growth factor-binding protein 7 (IGFBP7), tissue inhibitor of metalloproteinases-2 (TIMP-2) and [TIMP-2]⋅[IGFBP7] were measured in urine collected at enrollment, after 6 hours, and the following morning. Association between these biomarkers and the end point of moderate-severe AKI (KDIGO stage 2-3) occurring within 12 hours of each sample collection was examined using generalized estimating equation logistic regression. Performance for prediction of the AKI end point using two previously validated [TIMP-2]-[IGFBP7] cutoffs was also tested.Of 400 enrolled patients, 298 had sufficient sCr and UO data for classification by KDIGO AKI criteria: AKI stage 2 developed in 37 patients and AKI stage 3 in nine patients. All urinary biomarkers, sCr, and plasma cystatin C had statistically significant (P0.05) odds ratios (ORs) for the AKI end point. In a multivariable model of the urine biomarkers and sCr, only [TIMP-2]⋅[IGFBP7] and sCr had statistically significant ORs. Compared with [TIMP-2]⋅[IGFBP7]0.3 (ng/ml)(2)/1000, values between 0.3 and 2.0 (ng/ml)(2)/1000 indicated 2.5 (95% confidence interval [95% CI], 1.1 to 5.2) times the odds for the AKI end point and values2.0 (ng/ml)(2)/1000 indicated 11.0 (95% CI, 4.4 to 26.9) times the odds. Addition of [TIMP-2]⋅[IGFBP7] to a clinical model significantly improved area under the receiver-operating characteristic curve from 0.67 (95% CI, 0.61 to 0.78) to 0.77 (95% CI, 0.72 to 0.86) (P0.001); however, including both markers in the model was not significantly different from including either marker alone.Urinary [TIMP-2]⋅[IGFBP7] with pre-established cutoffs provides valuable information about risk for imminent AKI in the ED that is complementary to sCr and clinical risk factors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|